orthospinenews.com
/5 days ago
NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative…